17 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 22 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 17, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 2 | 6 | Completed 5, Terminated 1 |
Follow BCG: new trials by email Literature Review of BCG trials Research Report on BCG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer PF-08052667, Sasanlimab, BCG - Non-muscle Invasive Bladder Cancer | Phase 1 | Recruiting | Pfizer | 294 | 2025-11-06 | 2026-11-05 |
| First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b H107e, CAF®10b, H107e/CAF®10b - low adjuvant dose - Healthy | Phase 1 | Active not recruiting | Statens Serum Institut | 140 | 2024-03-14 | 2026-03-10 |
| Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines BCG Vaccine USP, Isoniazid, Rifampin - Tuberculosis | Phase 1 | Completed | Fred Hutchinson Cancer Center | 20 | 2022-12-06 | 2025-12-16 |
| Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC) BCG for Therapeutic Use - Non-muscular Invasive Bladder Cancer | Phase 1 | Completed | Chengdu CoenBiotech Co., Ltd | 10 | 2022-11-11 | 2024-04-05 |
| Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) Atezolizumab, BCG - Invasive Bladder Cancer | Phase 1 | Unknown | Fundacion Oncosur | 40 | 2020-02-03 | 2024-05-21 |
| EMaBS TB Vaccine Study ChAdOx185A, MVA85A, BCG - Safety, Immunogenicity | Phase 1 / Phase 2 | Completed | University of Oxford | 72 | 2019-07-01 | 2022-08-05 |
| Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer Avelumab, BCG - Bladder Cancer | Phase 1 / Phase 2 | Completed | University of Oklahoma | 18 | 2019-05-01 | 2024-02-14 |
| MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa MTBVAC, BCG - Tuberculosis | Phase 1 / Phase 2 | Completed | International AIDS Vaccine Initiative | 144 | 2018-05-14 | 2023-02-27 |
| Aerosol BCG Challenge Trial in Healthy UK Adults BCG, Saline placebo - Tuberculosis | Phase 1 | Completed | University of Oxford | 46 | 2016-03-07 | 2023-11-18 |
| Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults MTBVAC, BCG - Tuberculosis | Phase 1 / Phase 2 | Completed | Biofabri, S.L | 54 | 2015-09-01 | 2018-05-01 |
| Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents H4:IC31, H56:IC31, BCG - Tuberculosis | Phase 1 | Completed | Aeras | 84 | 2015-05-01 | 2019-11-18 |
| Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma Bacillus Calmette-Guérin (BCG) vaccine, Ipilimumab, Isoniazid - Metastatic Melanoma | Phase 1 | Terminated | Ludwig Institute for Cancer Research | 5 | 2014-03-01 | 2022-10-12 |
| Phase I Trial of DAR-901 DAR-901, BCG, Sterile saline - Tuberculosis | Phase 1 | Completed | Dartmouth-Hitchcock Medical Center | 59 | 2014-02-01 | 2016-08-02 |
| A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT HS-410, Placebo, BCG - Bladder Cancer | Phase 1 / Phase 2 | Terminated | Heat Biologics | 104 | 2013-12-01 | 2020-02-17 |
| Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer Mitomycin C - Urinary Bladder Neoplasm | Phase 1 | Completed | The University of Texas Health Science Center at San Antonio | 18 | 2012-03-01 | 2015-12-03 |
| BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients MAGE-A3 ASCI, BCG - Bladder Cancer | Phase 1 | Completed | Patrice Jichlinski | 23 | 2012-01-01 | 2015-02-04 |
| Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers VPM1002, BCG - Tuberculosis, Healthy | Phase 1 | Completed | Serum Life Science Europe GmbH | 80 | 2008-09-01 | 2010-05-20 |
| Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics BCG, Saline - Type 1 Diabetes Mellitus | Phase 1 | Completed | Massachusetts General Hospital | 25 | 2007-11-01 | 2013-11-05 |
| A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination BCG - Tuberculosis | Phase 1 | Completed | University of Oxford | 40 | 2007-08-01 | 2010-07-01 |
| Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine BCG - TB | Phase 1 | Completed | University of Oxford | 11 | 2004-02-01 | 2008-04-07 |
Showing 20 of 22. Sign in to see all of them.
Tuberculosis (11) · Urinary Bladder Neoplasms (8) · Non-Muscle Invasive Bladder Neoplasms (2) · Autoimmune Diseases (1) · Diabetes Mellitus, Type 1 (1) · Melanoma (1) · Neoplasms (1)
University of Oxford (5) · Aeras (1) · Biofabri, S.L (1) · Chengdu CoenBiotech Co., Ltd (1) · Dartmouth-Hitchcock Medical Center (1) · Fred Hutchinson Cancer Center (1) · Fundacion Oncosur (1) · Heat Biologics (1) · International AIDS Vaccine Initiative (1) · Ludwig Institute for Cancer Research (1) · Massachusetts General Hospital (1) · Patrice Jichlinski (1) · Pfizer (1) · Serum Life Science Europe GmbH (1) · Statens Serum Institut (1)
United States (7) · United Kingdom (6) · South Africa (4) · Spain (2) · Australia (1) · China (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · South Korea (1) · Switzerland (1) · Uganda (1)
Helen McShane (2) · Angelique Luabeya, MD (1) · Charles F. von Reyn, MD (1) · Daniel Castellano, MD (1) · David M Nathan, MD (1) · Gary Steinberg, MD (1) · Gavin Churchyard, PhD (1) · Helen I McShane (1) · Helen McShane, Professor (1) · James Kublin, MD, MPH (1) · Jim Kublin, MD (1) · Jonathan Cebon, MD, PhD (1) · Kelly Stratton, MD (1) · Linda-Gail Bekker, MD (1)
PMID 15502839, PMID 19529780, PMID 22905105, PMID 23290835, PMID 28498853, PMID 29552014, PMID 29685114, PMID 29915522, PMID 31120957, PMID 31416768, PMID 32382714, PMID 38621405, PMID 42008114, PMID 42648772
2019 (1)